Rock Springs Capital

Investor type Private Equity Firm
Founders Kris Jenner

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 101
Average round size
info
The average size of a deal this fund participated in
$92M
Portfolio companies 91
Rounds per year 12.62
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.10
Exits 60
Key employees 1
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

The main department of described VC is located in the Baltimore. The company was established in North America in United States.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular fund investment industries, there are Medical, Health Diagnostics. Among the most popular portfolio startups of the fund, we may highlight AveXis, Spark Therapeutics, Audentes Therapeutics. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.

Opposing the other organizations, this Rock Springs Capital works on 49 percentage points more the average amount of lead investments. The higher amount of exits for fund were in 2015. Deals in the range of 50 - 100 millions dollars are the general things for fund. The typical startup value when the investment from Rock Springs Capital is 500 millions - 1 billion dollars. The real fund results show that this VC is 16 percentage points less often commits exit comparing to other companies. The fund is generally included in 7-12 deals every year. The top activity for fund was in 2015. Despite it in 2019 the fund had an activity.

Besides them, we counted 1 critical employee of this fund in our database.

The typical case for the fund is to invest in rounds with 8-9 participants. Despite the Rock Springs Capital, startups are often financed by OrbiMed, Sofinnova Investments, Bay City Capital. The meaningful sponsors for the fund in investment in the same round are Deerfield, Wellington Management, Vivo Capital. In the next rounds fund is usually obtained by New Enterprise Associates, Omega Funds, CARB-X.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Rock Springs Capital:
Typical Co-investors
Rock Springs Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Rock Springs Capital:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Aivi Invest -
Bluegrass Angels Kentucky, Lexington, United States
California Institute for Regenerative Medicine California, San Francisco, United States
Cathexis Houston, Texas, United States
Changzhou Gaoxin Tou China, Jiangsu, Jintan
Disruptive Capital Finance England, London, United Kingdom
DMC Stratex Networks California, San Jose, United States
Higginbotham Strategic Investments -
Jumbo Sheen Group China, Guangdong, Shenzhen
Meta Capital -
Monarch Capital China, Hangzhou, Zhejiang
Movile Brazil, Paraíba, Sao Paulo
Presight Capital New City, New York, United States
Reti Televisive Italiane S.p.A. Cologno Monzese, Italy, Lombardia
The Good Stuff Beijing, Beijing, China
The Moinian Group New York, New York, United States
Tongcheng Zhongchuang Fund China, Jiangsu, Suzhou
Yabeo Capital Bavaria, Bayern, Germany
Zhongyan Chuangxin Touzi China, Guangdong, Shenzhen
Zhuhai Hecheng Zhiyi Ziben Guanli Youxian Gongsi China, Guangdong, Zhuhai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Freenome

Biotechnology
Health Care
Health Diagnostics
Personal Health
$300M07 Dec 2021 South San Francisco, California, United States

Patina

Health Care
$50M26 Oct 2021 Philadelphia, Pennsylvania, United States

CinCor Pharma

Pharmaceutical
Therapeutics
$143M12 Oct 2021 Cincinnati, Ohio, United States

Honor

Health Care
Home Health Care
Recruiting
Scheduling
Wellness
$70M05 Oct 2021 San Francisco, California, United States

Disc Medicine

Biotechnology
Health Care
Medical
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$43M21 Jul 2021 Cambridge, Massachusetts, United States

Imperative Care

Health Care
Medical
Medical Device
$260M15 Jul 2021 California, United States

dMed

Biopharma
Medical
Pharmaceutical
$50M10 Jul 2021 Shanghai, China
News
Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Amylyx Pharmaceuticals Raises $135M in Series C Financing

– Amylyx Pharmaceuticals, Inc. closed $135m in Series C financing.
Viking Global Investors led the round with participation from Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund and Falcon Edge.
– The company intends to use the funds for the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Rock Springs Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: